ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06173596
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06160414
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06079372
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06079359
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT06079281
- Locations
- 🇬🇧
Research Site, Stanmore, United Kingdom
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06071442
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06015750
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Danicopan Early Access Program
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05982938
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)
Active, not recruiting
- Conditions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05981092
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Recruiting
- Conditions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT05966467
- Locations
- 🇺🇸
Research Site, Boston, Massachusetts, United States
© Copyright 2024. All Rights Reserved by MedPath